Source: Press release
Disclosures: Gabbay is chief scientific and medical officer at the ADA.
June 17, 2021
2 min read

ADA updates standards of care to reflect new teplizumab, HF data

Source: Press release
Disclosures: Gabbay is chief scientific and medical officer at the ADA.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The American Diabetes Association issued updates to the 2021 Standards of Medical Care in Diabetes to reflect new data on the immunotherapy teplizumab for type 1 diabetes and heart failure benefits seen with SGLT2 inhibitors.

The updates, in annotations to the Living Standards of Care, also include new information on the medications’ effects on patients with chronic kidney disease.

Diabetes Words 2019
Source: Adobe Stock

“There have been so many exciting advancements in the field of diabetes, and that is why we are publishing more frequent updates to the Standards of Care,” Robert Gabbay, MD, chief scientific and medical officer at the ADA, said in a press release. “We are proud of the work done by our exceptional team of experts. The American Diabetes Association is committed to improving the lives of all those affected by diabetes through this publication of the most widely respected guidelines for diabetes health professionals, and updates like these are part of that commitment.”

Robert Gabbay

As Healio previously reported, the ADA published its 2021 Standards of Care in December, with new evidence-based updates ranging from diabetes technology and self-management education to socioeconomic disparities and COVID-19 vaccine recommendations.

Updates to the Living Standards of Care include information added to the following sections:

  • Section 2. Classification and Diagnosis of Diabetes has been revised to include evidence from a trial on anti-CD3 antibody teplizumab that demonstrated a delay in the development of type 1 diabetes for at-risk relatives of those with the disease. As Healio reported in May, an FDA advisory panel voted 10-7 in favor of recommending approval of teplizumab to delay development of type 1 diabetes in high-risk children and adults.
  • Section 10. Cardiovascular Disease and Risk Management has been updated to include new evidence from CV outcomes trials, including the VERTIS-CV, SCORED and SOLOIST-WHF, and EMPEROR-Reduced.
  • Section 11. Microvascular Complications and Foot Care has been amended to include the new evidence from DAPA-CKD and FIDELIO-DKD.

The ADA now updates and revises the online version of the Standards of Care throughout the year, with annotations for new evidence or regulatory changes that merit immediate incorporation. Updates to the Standards of Care are established and revised by the ADA’s Professional Practice Committee, a multidisciplinary team of 16 U.S. experts in the field of diabetes care, including physicians, diabetes care and education specialists, registered dietitians and others whose experience includes adult and pediatric endocrinology, epidemiology, public health, lipid research, hypertension, preconception planning and pregnancy care. Updates to section 10 have also been reviewed and approved by the American College of Cardiology, which endorses this section.

The complete, annotated Standards of Care can be accessed online at Diabetes Care. The Abridged Standards of Medical Care in Diabetes has also been updated and can be accessed online at Clinical Diabetes.